On Tuesday, the company’s share price rose 4% to its intraday high of ₹729.45 per share from its previous close of ₹700.45 after the company was shortlisted by the Commissionerate of Health Services, Government of Maharashtra.
In the exchange filling, Krsnaa Diagnostics Ltd has been shortlisted by the Commissioner of Healthcare Service, Maharashtra, for providing MRI and CT scan services in Maharashtra in district hospitals under the Authority.
Looking at its financials the company’s net revenue increased by 21% YoY from ₹121 crores in Q2FY23 to ₹147 crores in Q2FY24 and on the QoQ basis its net revenue rose by 11% from ₹132 crores in Q1FY24.
The net profit of the company fell by 38% YoY from ₹18 crores in Q2FY23 to ₹11 crores in Q2FY24 and on the QoQ basis, their net profit fell by 26% from ₹15 crores in Q1FY24.
The company has a low price-to-earnings ratio of 39 compared to its competitors, with a low debt-to-equity ratio of 0.04, a return on equity of 9%, a return on capital employed of 12%, and a net profit margin of 13%.
Krsnaa Diagnostics Ltd is a small-cap company with a market capitalization of ₹2,300 crores, the share price of the company rose by 35% in the last six months and 67% in the last year.
As per their shareholding pattern, the company’s promoter holds 27.8%, the foreign institutional investors hold 3.68%, the general public holds 49.88% and the domestic institutional investor holds 18.64%.
Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services to hospitals, medical colleges, and community health centers across India, with an extensive network across non-metro and lower-tier cities and towns.
Written by Sriram KV
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
